[PubMed] [Google Scholar]Ellington A

[PubMed] [Google Scholar]Ellington A.D., Szostak J.W. Using Apt8-2 would have several potential advantages, raising the possibility of developing new applications based on aptamer design. and and and and at 2.9 and 2.8 ? resolution. Biochemistry. 1981;20:2361C2370. [PubMed] [Google Scholar]Elkak A., Vjiayalakshmi M.A. Study of the separation of mouse monoclonal-antibodies by pseudobioaffnity chromatography using matrix-linked histidine and histamine. J. Chromatogr. 1991;570:29C41. [PubMed] [Google Scholar]Ellington A.D., Szostak J.W. selection of RNA molecules that bind specific ligands. Nature. 1990;346:818C822. [PubMed] [Google Scholar]Ellington A.D., Szostak J.W. Selection of single stranded DNA molecules that fold into specific ligand-binding structures. Nature. 1992;355:850C852. [PubMed] [Google Scholar]Fahrner R.L., Knudsen H.L., Basey C.D., Galan W., Feuerhelm D., Vanderlaan M., Blank G.S. Industrial purification of pharmaceutical antibodies: Development, operation, and validation of chromatography processes. Biotechnol. Genet. Eng. Rev. 2001;18:301C327. [PubMed] [Google Scholar]Fassina G., Ruvo M., Palombo G., Verdoliva A., Marino M. Novel ligands for the affinity-chromatographic purification of antibodies. J. Biochem. Linifanib (ABT-869) Biophys. Methods. 2001;49:481C490. [PubMed] [Google Scholar]Gagnon P. Purification tools for monoclonal antibodies. Validated Biosystems; Tucson, AZ: 1996. [Google Scholar]Gesteland R.F., Cech T.R., Atkins J.F. Cold Spring Harbor Laboratory Press; New York: 1999. The RNA world. [Google Scholar]Ghose S., Allen M., Hubbard B., Brooks C., Cramer S.M. Antibody variable region interactions with Protein A: Implications for the development of generic purification processes. Biotechnol. Bioeng. 2005;92:665C673. [PubMed] [Google Scholar]Harris L.J., Skaletsky E., McPherson A. Crystallographic structure of an intact IgG1 monoclonal antibody. J. Mol. Biol. 1998;275:861C872. [PubMed] [Google Scholar]Huse K., Bohme H.-J., Scholz G.H. Purification of antibodies by affinity chromatography. J. Biochem. Biophys. Methods. 2002;51:217C231. [PubMed] [Google Scholar]Kato K., Sautes-Fridman C., Yamada W., Kobayashi K., Uchiyama S., Kim H., Enokizono J., Galenha A., Kobayashi Y., Fridman W.H., et al. Structural basis of the conversation between IgG and Fc receptors. J. Mol. Biol. 2000;295:213C224. [PubMed] [Google Scholar]Keefe A.D., Schaub R.G. Aptamers as candidate therapeutics for cardiovascular indications. Curr. Opin. Pharmacol. 2008;8:1C6. [Google Scholar]Klussmann S. The aptamer handbook. WILEY-VCH; Weinheim, Germany: 2006. [Google Scholar]Martin W.L., West A.P., Jr, Gan L., Bjorkman P.J. Crystal structure at Mouse monoclonal to KI67 2.8 ? of an FcRn/heterodimeric Fc complex: Mechanism of pH-dependent binding. Mol. Cell. 2001;7:867C877. [PubMed] [Google Scholar]Matsumiya S., Yamaguchi Y., Saito J., Nagano M., Sasakawa Linifanib (ABT-869) H., Otaki S., Satoh M., Shitara K., Kato K. Structural comparison of fucosylated and nonfucosylated fc fragments of human immunoglobulin g1. J. Mol. Biol. 2007;368:767C779. [PubMed] [Google Scholar]Miyakawa S., Oguro A., Ohtsu T., Imataka Linifanib (ABT-869) H., Sonenberg N., Nakamura Y. RNA aptamers to mammalian initiation factor 4G inhibit cap-dependent translation by blocking the formation of initiation factor complexes. RNA. 2006;12:1825C1834. [PMC free article] [PubMed] [Google Scholar]Nakajima H., Kiyokawa N., Katagiri Y.U., Taguchi T., Suzuki T., Sekino T., Mimori K., Ebata T., Saito M., Nakao H., et al. Kinetic analysis of binding between Shiga toxin and receptor glycolipid Gb3Cer by surface plasmon resonance. J. Biol. Chem. 2001;276:42915C42922. [PubMed] [Google Scholar]Nakamura Y. Molecular mimicry between protein and tRNA. J. Mol. Evol. 2001;53:282C289. [PubMed] [Google Scholar]Ng E.W., Shima D.T., Calias P., Cunningham E.T., Jr, Guyer D.R., Adamis A.P. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 2006;5:123C132. [PubMed] [Google Scholar]Ngo T.T., Khatter N. Chemistry and preparation of affinity ligands useful in immunoglobulin isolation and serum-protein separation. J. Chromatogr. 1990;510:281C291. [PubMed] [Google Scholar]Oguro A., Ohtsu T., Svitkin Y.V., Sonenberg N., Nakamura Y. RNA aptamers to initiation factor 4A helicase hinder cap-dependent translation by blocking ATP hydrolysis. RNA. Linifanib (ABT-869) 2003;9:394C407. [PMC free article] [PubMed] [Google Scholar]Ohuchi S.P., Ohtsu T., Nakamura Y. Selection of RNA aptamers against recombinant transforming growth factor- type III receptor displayed on cell surface. Biochimie. 2006;88:897C904. [PubMed] [Google Scholar]Pellecchia M., Sebbel P., Hermanns U., Wuthrich K., Glockshuber R. Pilus chaperone FimC-adhesin FimH interactions mapped by TROSY-NMR. Nat. Struct. Biol. 1999;6:336C339. [PubMed] [Google Scholar]Porath J., Maisano F., Belew M. Thiophilic adsorptiona new method for protein fractionation. FEBS Lett. 1985;185:306C310. [PubMed] [Google Scholar]Romig T.S., Bell C., Drolet D.W. Aptamer affinity chromatography: Combinatorial chemistry applied to protein purification. J. Chromatogr. B Biomed. Sci. Appl. 1999;731:275C284. [PubMed] [Google Scholar]Sondermann P., Huber R., Oosthuizen V., Jacob U. The 3.2 ? crystal structure of the human IgG1 Fc fragmentCFcRIII complex. Nature. 2000;406:267C273. [PubMed] [Google Scholar]Tsumoto K., Umetsu M., Kumagai I., Ejima.